Inhalable Chitosan Nanoparticles for Sustained PAH Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) face challenges such as complex administration regimens, side effects, and the need for sustained drug release, particularly with prostacyclin analogues like Treprostinil and Nitric Oxide, which are difficult to stabilize and deliver effectively.
Innovation Solution
Development of polymeric nanoparticles encapsulated within crosslinked microparticles, specifically self-assembly amphiphilic chitosan-PEG-Cholanic acid or chitosan-PEG-Stearic acid, allowing for targeted, sustained, and controlled release of therapeutic agents like prostacyclin analogues, PPAR β agonists, and NO donors via inhalation or other routes, enhancing bioavailability and reducing dose frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous infusion or aerosol formulations are used for Treprostinil, then the drug can be delivered to patients, but the administration system becomes complex and patient compliance deteriorates
Solution Approach 1:
The patent employs a nested particle structure where nanoscale drug carriers are encapsulated within microscale particles. This hierarchical nesting allows the complex drug delivery function to be contained within a simple inhalable powder formulation, eliminating the need for infusion pumps or complex aerosol devices while maintaining effective drug delivery to the lungs.
Solution Approach 2:
The invention extracts the complex infusion pump or aerosol generator requirements by formulating the drug as a simple dry powder suitable for direct inhalation. The drug delivery function is separated from the complex administration device, allowing patients to self-administer through simple inhalation without mechanical assistance.
2Reliability
If prostacyclin analogues are administered to achieve vasodilation, then pulmonary vascular resistance decreases, but drug stability deteriorates due to rapid degradation
Solution Approach 1:
The patent applies preliminary protective action by encapsulating the unstable prostacyclin analogues within nanoscale carriers before administration. This pre-encapsulation protects the drug from degradation during storage and transport, and the controlled release mechanism ensures the drug remains stable until it reaches the target site in the lungs.
Solution Approach 2:
The invention uses composite material structures combining the prostacyclin analogue with stabilizing carrier materials. The composite nanoparticle system provides both the therapeutic drug and protective matrix, enabling the unstable drug to maintain stability while retaining its vasodilatory effectiveness.
3Ease of operation
If simple oral formulations are used for PAH treatment, then administration is simplified, but drug release control deteriorates leading to inadequate sustained release
Solution Approach 1:
The patent introduces dynamic control to the drug release process through stimuli-responsive materials. The inhalable particles are designed to remain stable during storage and administration, then dynamically change their release properties upon contact with lung environment triggers such as pH changes or specific enzymes, enabling sustained release without complex dosing regimens.
Solution Approach 2:
The invention segments the drug delivery process into controlled stages through the hierarchical particle structure. The nanoscale drug carriers are released from the microscale particles in a controlled sequence, providing sustained drug release over time while maintaining simple inhalable administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nano-micro-carrier system provides a simpler, more effective administration method for PAH treatment, improving bioavailability, reducing side effects, and enabling sustained drug release, thereby enhancing patient compliance and treatment outcomes.
Implementation Method 1
self-assembly amphiphilic chitosan-PEG-Cholanic acid, or chitosan-PEG-Stearic acid
Data Source
Figure 1~2(b)
Figure 3(a)~4(b)
Figure 5(a)~6
AI summary
Pharmaceutical formulations are described for use in the treatment of pulmonary arterial hypertension (PAH). The formulations comprise polymeric nanoparticles encapsulated within crosslinked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of PAH loaded within them (for example, prostacyclin synthetic analogs, PPAR β agonists and NO donors). Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.